City of Houston and local health care organizations receive $4M to treat mental health in students

Help granted

Through a $4 million grant, the city of Houston will be able to provide mental health treatment to at-risk students. Educational First Steps/Facebook

The city of Houston just received a major opportunity to help grow access to mental health treatment in children.

Thanks to a four-year $4 million grant from the United States Substance Abuse and Mental Health Services Administration, the city and its partner, Baylor College of Medicine, are launching the Be-Well Be-Connected program that provides at-risk students age six to 17 years old with mental health treatment.

The program will be led by Dr. Laurel Williams, associate professor of psychiatry at Baylor, division head for child and adolescent psychiatry and chief of psychiatry at Texas Children's Hospital. The treatment will include cognitive behavioral intervention for students with bipolar disorder and first episode psychosis, according to the release. The services will be provided in the child's home, which will ensure compliance.

"We do not have many places in Houston that have this capability to provide this level of intensity of services," Williams says in the release. "Having in-home therapy can allow the young person to stay engaged in their community and in their schools, which can promote wellness and reduction in symptoms burden more quickly."

Other Houston health centers, including Texas Children's Hospital, Harris Health System, Menninger Clinic, Harris Center, Veteran's Mental Health Care Line, Legacy Community Health Services, and DePelchin's Children's Center, will be involved with the program and the Mayor's Office of Education is the program manager of the grant.

"I created the Office of Education to support school districts in Houston because they are doing the essential work of guaranteeing that our next generation of adults is educated and ready for the future," says Mayor Sylvester Turner in the release. "The grant validates our efforts and more importantly will provide care on the frontlines of a key health issue involving young people."

Five independent school districts will also receive first level screening services and telemedical care. Families of the students receiving care will also receive support from the newly developed Texas State Child Mental Health Consortium.

"Houston and our surrounding area is primed to really take children's mental health care to the next needed level," says Williams in the release. "This SAMHSA grant opportunity coupled with the State Consortium will allow better coordination amongst services and an overall increase in available services — services that are desperately needed."

Texas doctors and researchers received millions for their transformational work in cancer prevention and treatment. Getty Images

A Texas organization has doled out millions to Houston cancer-fighting professionals

granted

Researchers at medical institutions across the state have something to celebrate. The Cancer Prevention and Research Institute of Texas has made 71 grants this week to cancer-fighting organizations that total a near $136 million.

"CPRIT's priorities of pediatric cancer research and cancers of significance to Texans highlight this large slate of awards," says Wayne Roberts, CPRIT CEO, in a release. "Investments are made across the cancer research and prevention continuum in Texas unlike any other state in the country."

New to the awards this time around is the Collaborative Action Program for Liver Cancer, which has been claimed by Baylor College of Medicine's Hashem B. El-Serag.

"Texas has the highest incidence rates of hepatocellular cancer in the nation," El-Serag says in a release from BCM. "Our CPRIT funded Center will house infrastructure to support and enhance research collaborations among liver cancer researchers; to educate providers, researchers and the general public on best practices and opportunities to reduce the burden of liver cancer; and to engage private and public entities in policy initiatives."

Houston organizations also received recruitment awards, which reward Texas organizations for bringing in great minds from across the world. According to the release, CPRIT has brought in a total of 181 scholars and 13 companies to the Lone Star State.

Of the 71 grants, 58 represent academic research, 10 prevention, and three product development research. Here are the ones awarded to Houston organizations.

The University of Texas MD Anderson Cancer Center

  • $900,000 granted for Shao-Cung Sun's research in regulation of CD8 T cell responses in antitumor immunity (Individual Investigator Research Award)
  • $897,483 granted for Alemayehu A. Gorfe's research in characterization and optimization of novel allosteric KRAS inhibitors (Individual Investigator Research Award)
  • $3 million granted for Hashem B. El-Serag's research at The Texas Collaborative Center for Hepatocellular Cancer (Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center Award)
  • $2.46 million to Jessica Hwang for patient-centered liver cancer prevention in the Houston community (Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Investigator-Initiated Research Awards)
  • $3.51 million for Kevin McBride's Recombinant Antibody Production Core at Science Park
  • $199,804 granted for Andrea Viale's epithelial memory of resolved inflammation as a driver of pancreatic cancer progression (High Impact High Risk Award)
  • $6 million for the recruitment of Christopher Flowers, M.D. (Recruitment of Established Investigator Awards)
  • $2 million for the recruitment of Kevin Nead, MD, MPhil (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $2 million for the recruitment of Alison Taylor, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $2 million for the recruitment of Mackenzie Wehner, MD, MPhil (Recruitment of First-Time, Tenure-Track Faculty Members Awards)

Baylor College of Medicine

  • $5.38 million granted for Steven J. Ludtke's new capabilities for cancer research in the TMC CryoEM Cores (Core Facility Support Awards)
  • $1.35 million granted for Bryan M. Burt's novel endoscope-cleaning port for minimally invasive cancer surgery (Early Translational Research Awards)
  • $199,500 granted for Yohannes T. Ghebre's Topical Esomeprazole for Radiation-induced Dermatitis (High Impact High Risk Award)
  • $199,920 granted for Robin Parihar's targeting of cancer associated fibroblasts with anti-IL-11-secreting CAR T cells (High Impact High Risk Award)
  • $2 million for the recruitment of Umesh Jadhav, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $2 million for the recruitment of Stanley Lee, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $2 million for the recruitment of Ang Li, MD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $1.29 million for Jane R. Montealegre's expansion of "a Community Network for Cancer Prevention to Increase HPV Vaccine Uptake and Tobacco Prevention in a Medically Underserved Pediatric Population"

Texas Medical Center

  • $5.44 million granted for William McKeon's Business-Driven Accelerator for Cancer Therapeutics (Core Facility Support Awards)

The University of Texas Health Science Center at Houston

  • $5.95 million granted for Zhiqiang An's Advanced Cancer Antibody Drug Modalities Core Facility (Core Facility Support Awards)
  • $2 million granted for Qingyun Liu's discovery and development of novel peptibody-drug conjugate for treating cancers of the digestive system (Early Translational Research Awards)
  • $199,998 granted for Leng Han's expression landscape and biomedical significance of transfer RNAs in cancer (High Impact High Risk Award)
  • $2 million for Lara S. Savas' Salud en Mis Manos that delivers "Evidence-Based Breast & Cervical Cancer Prevention Services to Latinas in Underserved Texas South and Gulf Coast Communities"

The University of Texas Medical Branch at Galveston

  • $3.55 million granted for William K. Russell's A Targeted Proteomics and Metabolomics Mass Spectrometry Core Facility at the University of Texas Medical Branch at Galveston (Core Facility Support Awards)
  • $199,996 granted for Brendan Prideaux's novel cellular-level imaging approach to assess payload drug distribution in tumors following administration of targeted drug delivery systems (High Impact High Risk Award)
  • $200,000 granted for Casey W. Wright's targeting ARNT and RBFOX2 alternative splicing as a novel treatment modality in lymphoid malignancies (High Impact High Risk Award)

The Methodist Hospital Research Institute

  • $200,000 granted for Robert Rostomily's development of a mini-pig glioma model and validation of human clinical relevance (High Impact High Risk Award)

Texas Southern University

  • $200,000 for Song Gao's alleviating SN-38-induced late-onset diarrhea by preserving local UGTs in the colon (High Impact High Risk Award)

University of Houston

  • $200,000 granted for Sergey S. Shevkoplyas' Novel High-Throughput Microfluidic Device for Isolating T-cells Directly from Whole Blood to Simplify Manufacturing of Cellular Therapies (High Impact High Risk Award)

Rice University

  • $2 million for the recruitment of Jiaozhi (George) Lu, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)
  • $1.67 million for the recruitment of Vicky Yao, PhD (Recruitment of First-Time, Tenure-Track Faculty Members Awards)

The Rose

  • $2 million for Bernice Joseph's Empower Her To Care Expansion

Legacy Community Health Services

  • $999,276 for Charlene Flash's "Increasing Breast and Colorectal Cancer Screening Rates for the Medically Underserved using Population Health Strategies at a Multi-County FQHC"
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.

View All Listings